Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein S2 (MRPS2) is a nucleus-encoded protein that forms a critical part of the small (28S) subunit of the mitochondrial ribosome, which is responsible for synthesizing the thirteen proteins encoded by mitochondrial DNA and essential for the assembly and function of the oxidative phosphorylation (OXPHOS) system[1][2][3]. Disruption of MRPS2 impairs assembly of the small mitoribosomal subunit, leading to compromised mitochondrial translation, inefficiency of ATP generation, and reduced cellular energy production. Pathogenic variants in MRPS2 are associated with a combined OXPHOS deficiency syndrome (OMIM #611971), which can manifest as lactic acidemia, hypoglycemia, and sensorineural hearing loss[1][2]. MRPS2 is not traditionally considered a direct drug target (receptor, enzyme, transporter or similar therapeutic target class)[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein S2 (MRPS2).